These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25457851)

  • 41. Clinical experience with adalimumab in anti-TNF-naïve patients with ulcerative colitis.
    Busquets D; Aldeguer X
    J Crohns Colitis; 2013 Jun; 7(5):e195. PubMed ID: 23219261
    [No Abstract]   [Full Text] [Related]  

  • 42. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytomegalovirus colitis complicating ulcerative colitis treated with adalimumab.
    Charles P; Ackermann F; Burdy G; Blétry O; Leport J; Kahn JE
    Scand J Gastroenterol; 2010 Apr; 45(4):509-10. PubMed ID: 20095878
    [No Abstract]   [Full Text] [Related]  

  • 44. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K; Stange EF
    Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract]   [Full Text] [Related]  

  • 46. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Intestine selective therapy].
    Maronde U
    MMW Fortschr Med; 2015 Jul; 157(13):80. PubMed ID: 26206050
    [No Abstract]   [Full Text] [Related]  

  • 48. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
    Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
    Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
    García-Bosch O; Gisbert JP; Cañas-Ventura A; Merino O; Cabriada JL; García-Sánchez V; Gutiérrez A; Nos P; Peñalva M; Hinojosa J; García-Planella E; Muñoz F; Calvet X; Panés J
    J Crohns Colitis; 2013 Oct; 7(9):717-22. PubMed ID: 23142005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis.
    Moein A; Lu T; Jönsson S; Ribbing J; Kassir N; Zhang W; Sperinde G; Zhang R; Tang M; Oh YS; Bruno R; Zhu R
    CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1244-1255. PubMed ID: 35851998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mirikizumab (Omvoh™) for ulcerative colitis.
    Hammerhøj A; Boye TL; Langholz E; Nielsen OH
    Trends Pharmacol Sci; 2024 Mar; 45(3):281-282. PubMed ID: 38262797
    [No Abstract]   [Full Text] [Related]  

  • 53. TNF-alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience.
    Nakase H; Chiba T
    Inflamm Bowel Dis; 2010 Apr; 16(4):550-1. PubMed ID: 19637380
    [No Abstract]   [Full Text] [Related]  

  • 54. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
    Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
    Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response to: infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.
    Tung J; Enders FT; Loftus EV
    J Crohns Colitis; 2014 Oct; 8(10):1327-8. PubMed ID: 24631323
    [No Abstract]   [Full Text] [Related]  

  • 56. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
    Tsai HH; Black C
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2023 Sep; 20(9):559. PubMed ID: 37553497
    [No Abstract]   [Full Text] [Related]  

  • 58. THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era.
    Kotze PG; Damião AO; Moraes AC
    Arq Gastroenterol; 2016; 53(1):3-4. PubMed ID: 27276096
    [No Abstract]   [Full Text] [Related]  

  • 59. Development of antibodies against humanized antitumor necrosis factor and loss of efficacy in a black spider monkey with inflammatory bowel disease.
    Eekman DA; Hoyer MJ; van Vugt RM; Wolbink GJ; Mulder CJ; Dijkmans BA
    J Clin Rheumatol; 2009 Feb; 15(1):39. PubMed ID: 19125133
    [No Abstract]   [Full Text] [Related]  

  • 60. Letter: Mucosal PCR for cytomegalovirus in refractory ulcerative colitis.
    Yoshino T; Nakase H; Matsuura M
    Aliment Pharmacol Ther; 2012 Oct; 36(8):811-2; author reply 812. PubMed ID: 22984956
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.